Sarah Jessica Parker's New Vision: Can VIZZ Drops End Reading Glasses?

SAN DIEGO, CA – January 14, 2026 – For millions, it’s an inevitable and frustrating rite of passage: the moment a menu, a text message, or the fine print on a label blurs into an indecipherable smudge. This is presbyopia, the age-related loss of near vision that sends उत्पादन128 million Americans scrambling for reading glasses. Now, a new pharmaceutical contender, backed by one of Hollywood’s most recognizable style icons, is aiming to change that daily ritual.

LENZ Therapeutics has launched a major consumer campaign, “Make it VIZZable,” for its newly approved eye drop, VIZZ, with actor and producer Sarah Jessica Parker as its public face. The campaign positions the once-daily prescription drop not just as a medical treatment, but as a lifestyle solution offering up to 10 hours of clear near vision, liberating users from the constant on-and-off hassle of “readers.”

“My age-related blurry near vision was a daily frustration, it got in the way of everything,” Parker stated in the announcement. “It’s so nice not having to reach for my reading glasses all the time; life just becomes more efficient... This is a gamechanger.”

Parker’s story, which details noticing her vision decline about 15 years ago and accepting reading glasses as her new reality, is designed to be universally relatable. By partnering with a celebrity known for her candor and influence, LENZ is betting it can transform the conversation around presbyopia from one of passive acceptance to one of active choice.

A New Player in a Crowded Field

While the celebrity endorsement has captured headlines, VIZZ enters a competitive and rapidly evolving market. It is not the first presbyopia-correcting eye drop to gain FDA approval. That distinction belongs to AbbVie’s VUITY (pilocarpine HCl ophthalmic solution), which launched in 2021 and was followed by other pilocarpine-based formulations. These earlier drops, however, received what some in the ophthalmology community describe as a “mixed reception,” with side effects like headaches and difficulty seeing in dim light tempering patient enthusiasm.

VIZZ aims to differentiate itself through its core chemistry. The drop’s active ingredient is aceclidine, making it the first and only FDA-approved therapy in its class. Unlike pilocarpine, which constricts the pupil but also engages the eye’s ciliary muscle, aceclidine is described as a “predominantly pupil-selective” miotic. In simpler terms, it focuses on shrinking the pupil to create a natural “pinhole effect,” which increases the eye’s depth of focus. This targeted mechanism is designed to significantly improve near vision without causing a “myopic shift”—the unintentional blurring of distance vision that can be a drawback of other miotics.

“We are honored to partner with SJP to introduce a unique new alternative to reading glasses,” said Eef Schimmelpennink, CEO of LENZ Therapeutics. “With VIZZ, we're excited to provide a revolutionary option that helps people regain the visual freedom they've been missing.”

The clinical data underpinning its July 2025 FDA approval is robust. In the CLARITY Phase 3 trials, VIZZ demonstrated a rapid onset, with many users seeing improvement within 30 minutes. Across the studies, a significant majority of participants gained three or more lines of near vision on a standard eye chart, an improvement that can mean the difference between needing glasses to read a phone and seeing it clearly.

The Price of Clear Sight

The potential market is enormous, encompassing nearly everyone over the age of 45. However, the success of VIZZ will hinge on more than just clinical efficacy and celebrity appeal. Key questions of access and affordability loom large. As a prescription-only product, patients must first visit an eye doctor, and the out-of-pocket cost will be a critical factor in adoption.

Competitor products hover around $80 for a 30-day supply, and it remains to be seen how LENZ will price VIZZ and, crucially, what level of coverage it will secure from insurance providers. Presbyopia treatments are often viewed as lifestyle enhancements rather than medical necessities by payers, posing a potential hurdle for reimbursement. LENZ has signaled a comprehensive commercial strategy, including a fully staffed sales force, broad sample distribution to eye care professionals, and partnerships with e-pharmacies to streamline access.

The “Make it VIZZable” campaign, which features Parker navigating New York City streets while effortlessly reading texts and scripts, is a clear attempt to frame the product’s value in terms of convenience and quality of life. The goal is to convince millions of consumers that freedom from reading glasses is worth the prescription and the price tag.

The View from the Clinic

Ultimately, the gatekeepers for VIZZ are the thousands of ophthalmologists and optometrists who will write the prescriptions. Initial sentiment from some clinical investigators is highly positive, with one eye doctor involved in the trials calling VIZZ a “disruptive paradigm shift” and a “welcome solution” that could become a new standard of care due to its favorable efficacy and safety profile.

However, the broader community of eye care professionals may be more circumspect, waiting to see how the drop performs in the real world outside the controlled environment of a clinical trial. They will be carefully evaluating patient satisfaction and tolerance for VIZZ’s own set of potential side effects. According to its prescribing information, the most common adverse reactions include instillation site irritation (20%), temporary dim vision (16%), and headache (13%).

For patients, setting realistic expectations will be key. These drops are not a permanent cure for presbyopia but a temporary, daily tool. As LENZ Therapeutics rolls out its ambitious launch, the true test will be whether the promise of convenience and clarity, amplified by a famous voice, is compelling enough to change the habits of a generation accustomed to reaching for their reading glasses.